Avalon Advisors LLC grew its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 16.5% in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 363,934 shares of the biopharmaceutical company’s stock after acquiring an additional 51,569 shares during the quarter. Avalon Advisors LLC’s holdings in Gilead Sciences were worth $27,437,000 as of its most recent SEC filing.
Other institutional investors have also made changes to their positions in the company. Parnassus Investments CA boosted its position in shares of Gilead Sciences by 2.5% in the fourth quarter. Parnassus Investments CA now owns 19,159,748 shares of the biopharmaceutical company’s stock valued at $1,372,604,000 after acquiring an additional 464,609 shares during the period. Hyman Charles D raised its stake in Gilead Sciences by 35.9% in the fourth quarter. Hyman Charles D now owns 4,164 shares of the biopharmaceutical company’s stock valued at $298,000 after purchasing an additional 1,100 shares in the last quarter. Accident Compensation Corp raised its stake in Gilead Sciences by 3.2% in the fourth quarter. Accident Compensation Corp now owns 64,097 shares of the biopharmaceutical company’s stock valued at $4,592,000 after purchasing an additional 2,000 shares in the last quarter. Financial Advisors Network Inc. raised its stake in Gilead Sciences by 1,964.0% in the fourth quarter. Financial Advisors Network Inc. now owns 127,330 shares of the biopharmaceutical company’s stock valued at $9,122,000 after purchasing an additional 121,161 shares in the last quarter. Finally, Harrington Investments INC raised its stake in Gilead Sciences by 6.7% in the fourth quarter. Harrington Investments INC now owns 24,320 shares of the biopharmaceutical company’s stock valued at $1,742,000 after purchasing an additional 1,536 shares in the last quarter. 77.65% of the stock is owned by institutional investors.
In other news, Director John C. Martin sold 50,000 shares of the company’s stock in a transaction that occurred on Friday, June 1st. The stock was sold at an average price of $68.13, for a total value of $3,406,500.00. Following the completion of the transaction, the director now owns 3,067,762 shares of the company’s stock, valued at $209,006,625.06. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director John Francis Cogan sold 5,836 shares of the company’s stock in a transaction that occurred on Friday, May 4th. The shares were sold at an average price of $65.09, for a total value of $379,865.24. Following the completion of the transaction, the director now directly owns 58,455 shares of the company’s stock, valued at approximately $3,804,835.95. The disclosure for this sale can be found here. In the last three months, insiders have sold 179,168 shares of company stock valued at $12,789,233. Insiders own 1.16% of the company’s stock.
NASDAQ GILD traded down $1.04 during trading on Tuesday, hitting $70.10. 297,951 shares of the company’s stock were exchanged, compared to its average volume of 7,240,231. The company has a current ratio of 2.84, a quick ratio of 2.75 and a debt-to-equity ratio of 1.32. The company has a market cap of $92.41 billion, a price-to-earnings ratio of 8.19, a PEG ratio of -6.18 and a beta of 1.15. Gilead Sciences, Inc. has a fifty-two week low of $64.27 and a fifty-two week high of $89.54.
Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Tuesday, May 1st. The biopharmaceutical company reported $1.48 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $1.67 by ($0.19). The business had revenue of $5.09 billion for the quarter, compared to analyst estimates of $5.40 billion. Gilead Sciences had a return on equity of 45.49% and a net margin of 14.03%. The firm’s revenue was down 21.8% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.23 EPS. sell-side analysts predict that Gilead Sciences, Inc. will post 5.75 earnings per share for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Thursday, June 28th. Shareholders of record on Friday, June 15th will be paid a dividend of $0.57 per share. This represents a $2.28 annualized dividend and a yield of 3.25%. The ex-dividend date is Thursday, June 14th. Gilead Sciences’s payout ratio is 26.64%.
A number of research analysts recently commented on GILD shares. BidaskClub raised Gilead Sciences from a “strong sell” rating to a “sell” rating in a research note on Wednesday, June 6th. Zacks Investment Research raised Gilead Sciences from a “sell” rating to a “buy” rating and set a $85.00 price target for the company in a research note on Thursday, April 19th. Barclays dropped their price target on Gilead Sciences from $95.00 to $90.00 and set a “buy” rating for the company in a research note on Wednesday, May 2nd. Piper Jaffray Companies started coverage on Gilead Sciences in a research note on Wednesday, May 30th. They issued a “buy” rating and a $85.00 price target for the company. Finally, Leerink Swann set a $72.00 price target on Gilead Sciences and gave the company a “market perform” rating in a research note on Wednesday, May 2nd. One investment analyst has rated the stock with a sell rating, ten have assigned a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $88.00.
About Gilead Sciences
Gilead Sciences, Inc is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands.
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.